Targeting STK36: Potential Drug and Biomarker (G27148)

Target Name: STK36

NCBI ID: G27148

STK36

Targeting STK36: Potential Drug and Biomarker

STK36 (also known as CILD46) is a protein that is expressed in various tissues throughout the body, including the brain, heart, liver, and muscle. It is a key regulator of cell growth and has been implicated in a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Recent studies have identified STK36 as a potential drug target and have shown that inhibiting its activity can have therapeutic effects in these diseases. This has led to a growing interest in developing compounds that can specifically target STK36 and modulate its activity.

One approach to targeting STK36 is to use small molecules, such as drugs that inhibit its phosphorylation or its DNA binding. These molecules have been shown to be effective in cell experiments and have the potential to be developed into drugs.

Another approach to targeting STK36 is to use antibodies that specifically recognize and target the protein. These antibodies have been shown to be effective in preclinical studies and have the potential to be developed into drugs.

In addition to its potential as a drug target, STK36 has also been identified as a potential biomarker for a number of diseases. This is because its expression is often altered in response to various environmental and genetic factors, which can be used as disease markers diagnosis and prognosis.

For example, studies have shown that STK36 expression is often increased in individuals with certain types of cancer, and that inhibiting its activity has been shown to be effective in treating these cancers. neurodegenerative diseases, and that inhibiting its activity has been shown to be effective in treating these diseases.

In conclusion, STK36 is a protein that has the potential to be a drug target and a biomarker for a number of diseases. Further research is needed to fully understand its role and to develop effective treatments.

Protein Name: Serine/threonine Kinase 36

Functions: Serine/threonine protein kinase which plays an important role in the sonic hedgehog (Shh) pathway by regulating the activity of GLI transcription factors (PubMed:10806483). Controls the activity of the transcriptional regulators GLI1, GLI2 and GLI3 by opposing the effect of SUFU and promoting their nuclear localization (PubMed:10806483). GLI2 requires an additional function of STK36 to become transcriptionally active, but the enzyme does not need to possess an active kinase catalytic site for this to occur (PubMed:10806483). Required for postnatal development, possibly by regulating the homeostasis of cerebral spinal fluid or ciliary function. Essential for construction of the central pair apparatus of motile cilia

The "STK36 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about STK36 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets